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Introduction Dichloroacetate (DCA, Cl 2 HC-COOH) is a unique xenobiotic that is both a potential environmental hazard and an investigational drug for the treatment of genetic mitochondrial diseases (Stacpoole et al., 2008) and certain hyperproliferative conditions, such as pulmonary arterial hypertension and cancer (Archer et al., 2008; Michelakis et al., 2010) . DCA is a byproduct of water chlorination, resulting in an exposure level of a few µg/kg/day to humans through consumption of municipal drinking water (Mughal, 1992) . DCA is also formed in vivo as a minor metabolite of certain chlorinated industrial solvents, including trichloroethylene and of pharmaceuticals, such as chloral hydrate and chloramphenicol (Stacpoole et al., 1998) . DCA has been considered as a potential health hazard based on extrapolated animal studies that showed multiple organ toxicities and hepatocarcinogenicity in inbred strains of rodents after chronic exposure to doses over 10 4 -fold higher than levels encountered through environmental exposure (Stacpoole et al., 1998) . However, similar doses of 10 -50 mg/kg/day have been used clinically for decades in treating acquired and congenital metabolic disorders and, recently, cancer (Stacpoole et al., 1998; Stacpoole et al., 2008; Michelakis et al., 2010) . Adverse effects from chronic DCA administration include mild increases in serum transaminases and mild to severe peripheral neuropathy, both of which are reversible and resolve gradually following discontinuation of the drug (Stacpoole et al., 1998) .
DCA is transported across cell membranes by the monocarboxylate transporter system and gains entry into the mitochondrial matrix via the mitochondrial pyruvate transporter (Stacpoole et al., 1998) . Within the matrix, DCA inhibits pyruvate dehydrogenase kinase (PDK) that inactivates the pyruvate dehydrogenase (PDH) complex. PDH is a gatekeeper enzyme that JPET #173195 5 muscle cells and cancer cells (Archer et al., 2008; Stacpoole et al., 2008; Michelakis et al., 2010) .
For these reasons, the mitochondrion is considered to be the primary cellular site of DCA action.
DCA is mainly eliminated through glutathione transferase zeta 1 (GSTZ1)-catalyzed dechlorination to glyoxylate, an intermediate that is further metabolized primarily by mitochondrial enzymes before excretion (Suppl. Fig.1 ). GSTZ1 is the only GST known to metabolize DCA. A trace amount of DCA can also be reductively dechlorinated to monochloroacetate in the blood (Shroads et al., 2008) . In vivo exposure to DCA causes a dose-and duration-dependent reduction in hepatic GSTZ1 expression and activity (Cornett et al., 1999; Ammini et al., 2003) .
Accordingly, DCA exhibits reduced plasma clearance and prolonged elimination half-life after repeated exposure (Stacpoole et al., 1998) .
GSTZ1 is a member of the cytosolic GST superfamily. Like other GSTs, GSTZ1 is present in the cytosol and is most abundantly expressed in the liver (Lantum et al., 2002) . Over the past decade, increasing numbers of drug metabolizing enzymes have been shown to exist in multiple subcellular compartments. These include several cytosolic GSTs (GSTA1, GSTA2, GSTA4, GSTP1, and GSTM1) that were recently found to be co-localized in the hepatic mitochondria (Raza et al., 2002; Gallagher et al., 2006) . Because DCA is known to be taken up by the mitochondria, we tested the postulate that this organelle is also a site of DCA biotransformation by examining the expression and activity of GSTZ1 in liver mitochondria from humans and rats.
Materials and Methods 1. Subcellular fractionation of human and rat livers. Adult female Sprague-Dawley (SD) rats were treated by gavage with tap water vehicle (n=9, control group) or 500 mg/kg/day DCA (n=11, DCA-treated group) for 8 weeks. Neuropathy was confirmed by measuring sciatic motor nerve conduction velocity and paw thermal response latency exactly as described elsewhere followed by sacrifice by decapitation (Calcutt et al., 2009) . Studies were performed following approval by the local IACUC. De-identified normal human liver samples, 1-2g, were collected during surgery under a protocol approved by Institutional Review Board of Shands Hospital at University of Florida (Gainesville, FL) for use in these studies. Livers were quickly removed, snap-frozen in liquid nitrogen and stored at -80°C until use.
Frozen liver was thawed and rinsed in ice-cold homogenizing buffer (0.25 M sucrose, 0.02 M Hepes-NaOH pH 7.4 and 0.1 mM phenylmethanesulfonyl fluoride). Rinsed livers were minced and homogenized in 5 volumes of homogenizing buffer with a motor-driven Teflon pestle for 4 complete strokes. After sedimenting the nuclei and cell debris at 600 X g, mitochondria were pelleted by centrifuging the supernatant at 13,000 X g for 20 min. The 13,000 x g supernatant was further subjected to differential centrifugation to isolate cytosol and washed microsomes (James et al., 1976) . The mitochondrial pellet was resuspended and washed twice before being taken up in the resuspension buffer (0.25 M sucrose, 0.01 M Hepes-NaOH pH 7.4, 0.1 mM dithiothreitol, 0.1 mM EDTA, 0.1 mM phenylmethanesulfonyl fluoride and 5% glycerol) in a volume equal to the liver weight. The washed mitochondria and cytosol were stored in aliquots at -80°C until use. All procedures were performed at 4°C or on ice. Cytosol and mitochondria were dialyzed with 10 kD MWCO Slide-A-Lyzer® Dialysis Cassettes (Thermo Scientific, Rockford, IL) against 1.15% KCl and 0.05 M potassium phosphate buffer pH 7.4 before use for assays. Protein concentrations were determined by the Bradford method (Bio-Rad, Hercules, CA) using bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO) as protein standard.
2. Subfractionation of liver mitochondria. Three 9-week old male SD rats were killed by decapitation and their livers were quickly isolated and rinsed in ice-cold homogenizing buffer to remove blood. The washed mitochondria were immediately isolated by procedures described above and subfractionated as follows. The suspension of washed mitochondria was diluted with swelling buffer (0.01 M Tris-HCl pH 7.4) to a final sucrose concentration of ~0.05 M and gently mixed with a magnetic stirrer at 4°C for 15 min. Shrinking buffer (2 M sucrose, 100 mM Tris-HCl pH 7.4) was then added into the swelled mitochondria to a final sucrose concentration of ~0.3 M.
After another 15 min stirring, the swollen-and-shrunk (shocked) mitochondria were centrifuged at 20,000 X g for 20 min. The supernatant yielded the intermembrane space (IMS) proteins. The pellet of shocked mitochondria was washed once, resuspended in homogenizing buffer and stored at -80°C. After 3 cycles of freezing-and-thawing, the shocked mitochondria were further subjected to 3 strokes of homogenization by Dounce homogenizer and 5 cycles of 5 sec sonication at 25 sec intervals. The shocked mitochondria were then centrifuged at 125,000 X g for 60 min to sediment the total mitochondrial membrane with the mitochondrial matrix remaining in the supernatant. The pellet containing the total mitochondrial membrane was resuspended in resuspension buffer. The IMS protein and matrix protein were concentrated by filtering through Amicon Ultra -15 ml filters of 10 kD MWCO (Millipore, Billerica, MA). were frozen and thawed three times, and then diluted to about 2 mg/ml in homogenizing buffer.
Electrophoresis and
After sonication and homogenization, the disrupted mitochondria were centrifuged at 125,000 X g for 60 min to pellet the total mitochondrial membrane. The soluble mitochondrial protein was collected from the supernatant and further concentrated using Amicon Ultra -15 ml filters of 10 kD MWCO.
Immunoprecipitation of mitochondrial GSTZ1 was carried out using the Pierce® Direct IP kit (Thermo Scientific) following provider's instructions. For each column, 10 µg of hGSTZ1C-1C antibody was coupled to 30 µl of 50% slurry of AminoLink® Plus coupling resin. Mitochondrial protein, 500 µg, was incubated with the antibody-coupled resin overnight at 4°C. After centrifuging the mixture to remove unbound proteins, the resin was washed with IP lysis/wash buffer supplied by the kit. The antigen was then eluted with the primary amine-containing, pH 2. (IDA) mode of operation was employed in which a survey scan from m/z 400-1200 was acquired followed by collision induced dissociation of the three most intense ions. Survey and MS/MS spectra for each IDA cycle were accumulated for 1 and 3 sec, respectively. 7. Protein Search Algorithm. Tandem mass spectra were extracted by ABI Analyst version 1.1.
All MS/MS samples were analyzed using Mascot (Matrix Science, London, UK; version 2.2.2). Protein identifications were accepted if they could be established at greater than 99.0% probability and contained at least 2 identified unique peptides. Protein probabilities were assigned by the Protein Prophet algorithm (Nesvizhskii et al., 2003) . Expression and activity of GSTZ1 in hepatic mitochondria. In liver mitochondria of both human and rat, our hGSTZ1 antibody cross-reacted with a protein that migrated similarly to the purified hGSTZ1 and the cytosolic GSTZ1 at ~24 kD (Fig. 1) . GSTZ1 immunoreactivity was more intense in cytosol than in mitochondria for a given amount of protein, indicating a more abundant expression of GSTZ1 in cytosol. To assure that the detection of mitochondrial immunoreactive GSTZ1 was not due to cytosolic contamination, mitochondrial purity was established by demonstrating minimal detection of the cytosolic marker aldehyde dehydrogenase 1A1 (ALDH1A1). Cytosolic expression of GSTZ1 was 2.4-fold and 3.9-fold higher than mitochondrial in human and rat livers, respectively, on a per-milligram-of-protein basis (Table 1) . This is consistent with the 2.5 -3-fold higher activity of GSTZ1 in cytosol than in mitochondria, as determined using 14 C-DCA as substrate. About 86% [human: 40.1/(40.1+6.78); rat: 0.92/(0.92+0.14)] of cellular GSTZ1 was located in cytosol and 14% was located in mitochondria, based on the higher yield of protein from cytosol than mitochondria and assuming that 30 mg mitochondria were present per gram liver (Fleischer et al., 1979) .
GSTZ1 is known to be inactivated by DCA after repeated exposure (Cornett et al., 1999) .
This was confirmed by the marked reduction in both the expression and activity of cytosolic GSTZ1 in rats treated with DCA 500 mg/kg/day for 8 weeks ( Fig.1 and Table 1 ). The expression of mitochondrial GSTZ1 in these rats was also reduced to ~10% of control levels and the specific activity was reduced to below the detection limit (Table 1) . Coincidentally, we observed a strong induction of cytosolic marker ALDH1A1 in the DCA-treated rats compared to control rats. Our GSTZ1 antibody cross-reacted with an unknown protein in rat mitochondria that appeared 1 -2 kD larger than GSTZ1 on SDS-PAGE (Fig.1) . The cytosolic expression of this cross-reacting protein changed from not detectable in fresh control livers to barely detectable in frozen control livers to readily-detectable in frozen DCA-treated livers (Suppl. Fig. 2 ). This pattern of expression is similar to those of mitochondrial matrix protein cyclophilin D (CypD) and intermembrane space protein cytochrome C (CytC). Preliminary investigation of this protein by immunoprecipitation and LC-MS/MS protein identification suggested that it was a mitochondrial matrix protein with less than 3% sequence identity to hGSTZ1 (NCBI Blastp). This result was further supported by its submitochondrial localization in the matrix (see below, Fig. 2A ).
Mitochondrial GSTZ1 is localized in the matrix. The mitochondrion has a double membrane structure that divides the organelle into four compartments: the outer membrane (OM), the intermembrane space (IMS), the inner membrane (IM) and the matrix. To investigate if DCA biotransformation occurs in the same mitochondrial compartment as its pharmacodynamic action, we examined GSTZ1 expression and activity in the washed mitochondria and three submitochondrial fractions: IMS, the matrix and the membranes (including OM and IM) (Fig. 2) .
GSTZ1 expression and catalytic activity were greatest in the matrix, being nearly 3 times higher than in washed mitochondria. Low levels of GSTZ1 expression and activity were found in the membrane fraction, which might be due to incomplete release of matrix protein from the shocked mitochondria during fractionation. However, neither expression nor activity was detectable in the IMS. We also confirmed that GSTZ1 exists in cytosol, but not in microsomes. Similar levels of GSTZ1 expression were detected in cytosol and mitochondrial matrix. However, the cytosolic marker ALDH1A1 was only detected in cytosol but not in mitochondrial matrix. This also indicated that the presence of GSTZ1 in mitochondria was not due to cytosolic contamination.
LC-MS/MS identification of the mitochondrial GSTZ1. The identity of the mitochondrial GSTZ1
was verified by immunoprecipitating the antibody-reactive proteins from human and rat liver mitochondria and analyzing the tryptic peptide sequences by LC-ESI-QTOF. We used the matrix protein of rat mitochondria and the soluble protein of human mitochondria for immunoprecipitation. The immunoprecipitated GSTZ1 of human liver mitochondria was identified with 3 unique peptides in 4 unique spectra, covering 12% (27/216) of the hGSTZ1 protein sequence (Fig.3 and Table 2 ). Although the coverage was relatively low, a clear ladder of fragmentation was shown in the peptide, 41 DGGQQFSK 48 (Fig. 4) , which increased our confidence of the protein identification. Of the immunoprecipitated rat GSTZ1, 2 unique peptides covering 13% (28/216) of the rat GSTZ1 protein sequence were identified ( Fig. 3 and Table 2 ).
Kinetic study of cytosolic and mitochondrial GSTZ1. Rat mitochondrial GSTZ1 had a 2.5-fold higher App K m for GSH than the cytosolic GSTZ1, whereas the App K m s for DCA were identical (Table 3 ). With either GSH or DCA as the variable substrate, the App V max values of cytosolic GSTZ1 were 3 times those of mitochondrial GSTZ1, in good accordance with the 3.9-fold higher expression of cytosolic GSTZ1 per mg protein (Table 1) . Lineweaver-Burk plots of cytosolic GSTZ1 and mitochondrial GSTZ1 with GSH and DCA as substrates were shown for one representative rat in Fig. 5 .
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Discussion
The mitochondrion is the primary site of DCA's pharmacodynamic action. However, its role in DCA biotransformation has been largely overshadowed by the prominence of cytosol and endoplasmic reticulum in drug metabolism. In this study we demonstrate the mitochondrion to be a second site of DCA biotransformation in a reaction catalyzed by GSTZ1, an enzyme colocalized in the mitochondrial matrix and cytosol. Furthermore, GSTZ1 expression and activity in the liver mitochondria are susceptible to DCA inactivation, as occurs with the cytosolic form of GSTZ1. We also verified partial sequences of mitochondrial GSTZ1 by LC-MS/MS and compared the kinetics between cytosolic and mitochondrial GSTZ1 using DCA and GSH as substrates.
The level of GSTZ1 expression is similar in cytosol and mitochondrial matrix, whereas it is about 70% less in intact mitochondria on a per milligram-of-protein basis. Although a low level of cytosolic contamination was to be expected in the liver mitochondria isolated by differential centrifugation, we confirmed the authenticity of mitochondrial GSTZ1 by demonstrating minimal co-detection of cytosolic marker ALDH1A1. Moreover, we would expect to detect any cytosoloriginated GSTZ1 in the IMS fraction, which was obtained from the first supernatant of osmotically-shocked mitochondria. In fact, GSTZ1 was detected in the mitochondrial matrix at an intensity similar to that in cytosol, but without detectable ALDH1A1 (Fig. 2) . This evidence firmly established the mitochondrial origin of GSTZ1. In light of this finding, we searched the literature for GSTZ1 identification from studies of mitochondrial proteome. Indeed, GSTZ1 was identified in the mitochondrial proteome of mouse liver, heart, and kidney (Mootha et al., 2003) . Consistent with our finding, GSTZ1 was shown in the proteome of mitochondrial matrix but not intermembrane space of rat liver (Forner et al., 2006) . and GSTM1) that are currently known to co-localize in cytosol and mitochondrial matrix have similar molecular sizes and identical N-terminals in both compartments (Raza et al., 2002; Gallagher et al., 2006) . Mitochondrial import studies of GSTA4 and GSTM1 suggest non-cleaved internal targeting sequences at the C-terminal and N-terminal, respectively, of the mature GST proteins (Robin et al., 2003; Goto et al., 2009 ). Furthermore, protein kinase A (PKA)-and protein kinase C (PKC)-catalyzed phosphorylation has been shown to facilitate GSTA4 translocation to the matrix (Robin et al., 2003) . The present study of cytosolic and mitochondrial GSTZ1 also suggests their similar molecular weights, as shown by the indistinguishable rates of migration on SDS-PAGEs. To obtain more insight into protein structure, we attempted direct N-terminal sequencing for human mitochondrial GSTZ1 immobilized on PVDF membrane. However, the study failed due to the blocked N-terminus, which was also observed for rat cytosolic GSTZ1 (Tong et al., 1998b) . On the other hand, one tryptic peptide of human mitochondrial GSTZ1
identified by LC-MS/MS shared the same identity as the C-terminal amino acids of cytosolic Cys16 to Ala caused dramatic increases in K m s for GSH with various substrates (Board et al., 2003; Ricci et al., 2004) . As demonstrated in mouse GSTA4, the mitochondrial form is more heavily phosphorylated than the cytosolic form while possessing the same primary protein sequence (Robin et al., 2003) . If post-translational modification is involved in the GSTZ1 translocation to mitochondria, modifications of residues around the GSH binding pocket may alter the conformation of this region in mitochondrial GSTZ1 and thus contribute to the reduced GSH affinity. Nevertheless, GSH is present at concentrations (2-10 mM) well above the K m values in cytosol and mitochondria (Hansen et al., 2006) ; therefore, the difference in K m for GSH should not affect or limit the rates of DCA dechlorination in either compartment under physiological conditions.
Inspection of the DCA metabolic pathway reveals that all but one of the enzymes involved in secondary biotransformation are located in the mitochondria (Suppl. Fig.1 ). Our study establishes a novel role of the mitochondrion in DCA primary biotransformation, which may allow efficient degradation of glyoxylate in mitochondria and therefore explain the fact that a large majority of DCA metabolites observed in vivo are derived from mitochondrial pathways of secondary biotransformation (Lin et al., 1993; James et al., 1998) . However, generation of glyoxylate in the mitochondria may perturb the mitochondrial redox homeostasis because glyoxylate is an electrophile and may react with cellular macromolecules (Anderson et al., 2004) .
DCA-induced inactivation of GSTZ1 was observed in both cytosol and mitochondria of rats treated with 500 mg/kg/day of DCA for 8 weeks. However, the question remains as to whether or not lower environmental and therapeutic doses of DCA would affect GSTZ1 similarly in the two compartments.
We unexpectedly observed a marked induction of cytosolic ALDH1A1 in the livers of DCA-treated rats, which we speculate to be caused by an increased level of oxidative stress in the livers due to DCA treatment. ALDH1A1 is a cytosolic and inducible isoform of the aldehyde dehydrogenase family that catalyzes the oxidation of medium-chain aliphatic aldehydes, including 4-hydroxynonenal and malondialdehyde (Alnouti and Klaassen, 2008) . This is noteworthy The GSTZ1 antibody-cross-reacting protein was shown to be a rat mitochondrial matrix protein but exhibited varying degrees of expression in the cytosol depending on the liver condition. Its appearance in the cytosol of frozen control liver could be due to mitochondrial membrane lesions caused by freezing the liver and thawing it on ice (Pallotti and Lenaz, 2007) . It is notable that the expression of this protein was further increased in the DCA-treated cytosol. We speculate that this altered expression is a combined result of freeze-thawing the liver and further leakage of mitochondrial protein due to DCA treatment. DCA can induce oxidative stress (Larson and Bull, 1992; Hassoun et al., 2010) , a condition detrimental to mitochondrial membrane integrity (Fulda et al., 2010 ).
In conclusion, we demonstrate that the mitochondrion, known to be the site of DCA's pharmacological action on PDK, is also a site of DCA biotransformation. The reaction is catalyzed by GSTZ1, an enzyme co-localized in the cytosol and the mitochondrial matrix. GSTZ1 of both compartments is inactivated by high doses of DCA and exhibits the same This article has not been copyedited and formatted. The final version may differ from this version. GSTZ1 expression / mg protein.
b Cytosolic yield was calculated based on the total cytosolic protein recovered experimentally.
Mitochondrial yield was standardized to 30 mg mitochondrial protein per gram liver to correct for loss of mitochondria during differential centrifugation (Fleischer et al., 1979) . b Underlined amino acids were identified by MS with modifications.
c Pyroglutamate (Pyro-Glu) formed from cyclization of N-terminal glutamine.
